论文部分内容阅读
卵巢癌在临床诊断时多为晚期,治疗后约40%～60%的患者可能复发,原因之一在于传统化疗的“真正”有效剂量有限。有必要依据卵巢癌的病因学和生化特征,探寻具有高度选择性的靶向治疗,以提高药物的“真正”有效剂量。高促性腺激素学说是卵巢癌的病因之一,下丘脑-垂体激素相关受体在卵巢癌中呈现出异常表达,且在机体的分布相对较局限,因此,这些受体可能会成为选择性破坏卵巢肿瘤细胞更为理想的靶点,基于此设计的受体靶向化疗将在卵巢癌治疗中体现出相当的优势和应用前景。
Ovarian cancer is mostly late in clinical diagnosis. About 40% to 60% of patients may relapse after treatment. One of the reasons for this is that the “true” effective dose of traditional chemotherapy is limited. It is necessary to look for highly selective targeted therapies based on the etiology and biochemical characteristics of ovarian cancer in order to increase the “true” effective dose of the drug. Hormone-gonadotropin theory is one of the causes of ovarian cancer, hypothalamic-pituitary hormone-related receptors showed abnormal expression in ovarian cancer, and the distribution in the body is relatively limited, therefore, these receptors may be selectively destroyed Ovarian tumor cells is a more ideal target, based on which the design of receptor-targeted chemotherapy in ovarian cancer treatment will show considerable advantages and application prospects.